Albemarle Corporation 1997 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1997. Albemarle Corporation is a major producer of specialty and fine chemicals, operating through two global business units: Polymer Chemicals (flame retardants, catalysts, polymer curatives) and Fine Chemicals (bromine chemicals, pharmaceutical and agricultural intermediates). The company operates manufacturing facilities in the United States, France, Belgium, and Japan. In 1996, the company sold its Olefins Business to Amoco, significantly altering its operational scope.
Key Financial Metrics (Year Ended Dec 31, 1997)
| Metric | 1997 | 1996 | 1995 |
|---|---|---|---|
| Net Sales | $829.9 million | $854.5 million | $1,244.2 million |
| Gross Profit | $261.4 million | $243.1 million | $277.0 million |
| Gross Margin | 31.5% | 28.5% | 22.3% |
| Operating Profit | $120.7 million | $93.4 million | $117.0 million |
| Net Income | $80.0 million | $156.1 million | $78.2 million |
| Diluted EPS | $1.44 | $2.65 | $1.18 |
| Cash from Operations | $98.8 million | $28.5 million | $116.2 million |
| Capital Expenditures | $85.3 million | $90.4 million | $112.4 million |
| Total Assets | $888.2 million | $846.3 million | $1,204.5 million |
| Long-Term Debt | $91.4 million | $24.4 million | N/A |
| Cash & Equivalents | $34.3 million | $14.2 million | $33.1 million |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 3% to $829.9 million. Excluding the first two months of 1996 sales from the sold Olefins Business, organic sales increased 7% due to higher shipments in agricultural chemicals, pharmaceutical intermediates, and organometallics. This growth was partially offset by the strengthening U.S. dollar impacting foreign sales.
- Profitability: Operating profit increased 29.2% to $120.7 million. Gross margin improved to 31.5% from 28.5% due to better plant utilization and cost reduction programs, despite higher energy costs.
- Net Income: Net income dropped significantly to $80.0 million from $156.1 million in 1996. The 1996 figure included a one-time gain of $158.2 million from the sale of the Olefins Business, which was absent in 1997.
- Debt: Long-term debt increased to $91.4 million from $24.4 million as the company utilized its credit facility to fund operations and capital projects.
Guidance, Outlook, and Risks
- Outlook: Management expects to face challenges from a strong U.S. dollar in 1998. The company anticipates continued growth in bulk ibuprofen sales and expects new flame retardant products to gain traction later in 1998 following customer qualification.
- Capital Spending: Capital spending is expected to increase significantly over the next few years to expand capacity at existing facilities, primarily funded by operating cash flow and additional debt.
- Risks:
- Currency: A strong U.S. dollar negatively impacts revenue from European and Asia Pacific operations.
- Market Conditions: Economic turmoil in Asia poses a risk, though the company notes its products are often used in goods sold in the U.S. and Europe.
- Environmental: The company faces potential liabilities under Superfund laws. While current accruals are $8.9 million, there is a reasonable possibility of additional remediation costs up to $6.8 million.
- Year 2000: The company is implementing systems to ensure Y2K compliance, with estimated expenditures of $5 million over two years.
Investor Verification Checklist
- Verify the impact of the strong U.S. dollar on 1998 revenue projections, as foreign sales comprise a significant portion of operations.
- Confirm the timeline and customer qualification status for the new flame retardant products (SAYTEX HP-7010 and RB-100) expected to drive growth in 1998.
- Review the environmental liability accruals ($8.9 million) and the potential for additional costs ($6.8 million) to assess balance sheet risks.
- Monitor the utilization of the $500 million credit facility, as long-term debt increased substantially in 1997.
- Assess the commercial success of bulk naproxen sales, which commenced in late 1997 but faced initial disappointment in sales pace.